Get the Stockscreener App
0.7816
1.23%
-0.0097
After Hours:
.78
-0.0016
-0.20%
Rein Therapeutics Inc stock is traded at $0.7816, with a volume of 336.47K.
It is down -1.23% in the last 24 hours and down -19.52% over the past month.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
See More
Previous Close:
$0.7913
Open:
$0.8
24h Volume:
336.47K
Relative Volume:
0.42
Market Cap:
$66.86M
Revenue:
-
Net Income/Loss:
$-50.21M
P/E Ratio:
-0.4102
EPS:
-1.9053
Net Cash Flow:
$-16.61M
1W Performance:
-7.39%
1M Performance:
-19.52%
6M Performance:
-49.57%
1Y Performance:
-46.47%
1-Day Range:
$0.76
$0.83
1-Week Range:
$0.7577
$0.9321
52-Week Range:
$0.7577
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.7816 | 67.69M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNTX|Rein Therapeutics Inc|Price:0.791|Chg%:-0.009 - TradingKey
Rein Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNTX - TradingView
Rein Therapeutics (RNTX) Proxy filing Summary - Quartr
Rein Therapeutics (RNTX) Q4 2025 earnings summary - Quartr
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Rein Therapeutics Shareholders Approve Governance and Stock Changes - TipRanks
Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com South Africa
Rein Therapeutics expands phase 2 IPF trial to Germany - Investing.com
Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial - marketscreener.com
Rein Therapeutics expects initial lung-trial data in 2H 2026 - Stock Titan
Rein Therapeutics Price Target Announced at $4.00/Share by Maxim Group - Moomoo
Rein Therapeutics (RNTX) Gains Buy Rating and $4 Price Target fr - GuruFocus
RNTX Initiates Coverage On by Maxim Group -- Rating Set to Buy - GuruFocus
Rein Therapeutics (RNTX) AGM 2026 Summary - Quartr
Transcript : Rein Therapeutics Inc.Shareholder/Analyst Call - marketscreener.com
RNTX: All agenda items, including director elections and share authorization, were approved - TradingView
RNTX: All agenda items, including director elections and share increase, were approved - TradingView
Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support LevelMcClellan Summation - DonanımHaber
Price to sales forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Enterprise value to EBITDA forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Enterprise value to revenue forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Price to earnings forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Price to earnings forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Price to sales forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Enterprise value to EBIT forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management Improves - dars.gov.et
RNTXRein Therapeutics Inc Latest SEC Filings - Finviz
Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rein Therapeutics Inc.(NasdaqCM: RNTX) added to Russell 3000E Value Benchmark - marketscreener.com
Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX) - TradingView
RNTX Forecast — Price Target — Prediction for 2027 - TradingView
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrower‑than‑expected loss as clinical pipeline advances - dars.gov.et
Rein Therapeutics Inc (RNTX) Institutional Confidence - TradingKey
Rein Therapeutics (RNTX) Surges 5.87% as Stock Tests Key Resistance at $0.97Sweep Order Flow - DonanımHaber
RNTX Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionFinal Results - dars.gov.et
Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance
Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com - Investing.com Nigeria
Rein Therapeutics (RNTX) Slips 1.6% as Stock Tests Key Support at $0.89Small Cap Breakouts - newsline.com
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherPost-Earnings Reaction - newsline.com
Rein Therapeutics enrolls 16 patients in lung fibrosis trial - Investing.com
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan
Rein Therapeutics Inc Stock (RNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):